SCM
CRNX

Sterling Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Sterling Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6K Sell
364
-271
-43% -$10.1K ﹤0.01% 2065
2026
Q1 		$23.1K Buy
635
+40
+7% +$1.79K ﹤0.01% 1970
2025
Q4 		$27.7K Buy
595
+376
+172% +$16.7K ﹤0.01% 2061
2025
Q3 		$9.12K Buy
219
+1
+0.5% +$32 ﹤0.01% 2532
2025
Q2 		$6.27K Buy
218
+120
+122% +$3.71K ﹤0.01% 2394
2025
Q1 		$3.29K Buy
98
+8
+9% +$299 ﹤0.01% 2369
2024
Q4 		$4.6K Buy
90
+10
+13% +$559 ﹤0.01% 2497
2024
Q3 		$4.09K Buy
+80
New +$4.13K ﹤0.01% 1841

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's CRNX Position: Q2 2026 in Review

Sterling Capital Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 43% in Q2 2026, selling an estimated $10.1K and leaving 364 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

Sterling Capital Management first reported a position in CRNX in Q3 2024 and has held it in 8 quarters since. The position peaked at $27.7K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Sterling Capital Management held 364 shares of Crinetics Pharmaceuticals worth $13.6K as of Q2 2026.
  • Sterling Capital Management sold 271 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $10.1K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2065 holding.
  • Sterling Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Crinetics Pharmaceuticals position peaked at $27.7K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.